Shanghai Rendu Biotechnology Co., Ltd. Class A
SSSE:68819343.78
CNY
+0.39
(+0.90%)
ISIN
CNE1000059K5
Return %
Stock
S&P 500
1Y
-6.51
14.39
3Y
4.16
81.42
5Y
- -
68.62
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ming Hui Yu
- Full Time Employees
- 239
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Shanghai China
- IPO Date
- Mar 30, 2022
- Website
- rdbio.com
- Similar Companies
- Business
- Shanghai Rendu Biotechnology Co., Ltd. is a China-based in vitro diagnostic (IVD) company specializing in the research, development, manufacturing, and commercialization of molecular diagnostic reagents and automated testing instruments. Founded in 2007 and headquartered in Shanghai, China, the company focuses on RNA isothermal amplification technology for clinical testing across infectious diseases, reproductive health, and personalized medicine. Shanghai Rendu Biotechnology operates through two primary business segments: Diagnostic Reagents and Diagnostic Instruments. Its core product portfolio includes RNA isothermal diagnostic kits based on proprietary Simultaneous Amplification and Testing (SAT) technology; sexually transmitted infection (STI) diagnostic assays for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Ureaplasma urealyticum (UU), and Human Papillomavirus (HPV); respiratory infection diagnostic panels covering Mycobacterium tuberculosis (TB), Mycoplasma pneumoniae, Influenza A and B viruses, and Respiratory Syncytial Virus (RSV); blood-borne virus detection kits including Hepatitis B (HBV) RNA and Hepatitis C (HCV) RNA assays; nucleic acid extraction reagents and quality control products; and fully automated molecular diagnostic systems, notably the AutoSAT and SanAuto series of automated nucleic acid extraction and detection analyzers, along with related laboratory consumables and technical support services. The company primarily serves general hospitals, specialized medical institutions, maternal and child health centers, centers for disease control and prevention (CDCs), independent clinical laboratories, and blood transfusion centers across mainland China and select international markets. In recent developments, Shanghai Rendu Biotechnology has accelerated the commercial rollout of its next-generation AutoSAT high-throughput, sample-to-result automated testing platforms and expanded its multiplex RNA diagnostic assay menu. The company has secured additional National Medical Products Administration (NMPA) market registrations for expanded multi-pathogen respiratory panels and comprehensive STI screening kits, entered into strategic clinical research partnerships with leading tertiary healthcare institutions to advance RNA-based active infection diagnostic guidelines, and pursued international regulatory certifications to expand its distribution footprint across overseas IVD markets.